Blueprint Medicines, a Sanofi Company, Announces Four-Year PIONEER Data Showing Sustained Benefit and Long-Term Safety of AYVAKIT (avapritinib) in Indolent Systemic Mastocytosis

Real-world study of AYVAKIT highlights improvement across ISM symptoms 12 data presentations at 2026 AAAAI Annual Meeting reflect companys leadership in elevating SM care CAMBRIDGE, Mass., Feb. 28, 2026 /PRNewswire/ Blueprint Medicines, a Sanofi company, today announced AYVAKIT (avapritinib) data showing clinically meaningful outcomes and a well-tolerated long-term safety profile in […]

Source: The Times Of Bengal

Read More